Zachary Hornby, Boundless Bio CEO
March 21, 2024 07:03 AM EDT
Financing
Startups

Bound­less Bio seeks $88M in IPO as it runs two Ph1 can­cer tri­als

Kyle LaHucik

Senior Reporter

The spring IPO class is here.

Bound­less Bio, a can­cer biotech with two dif­fer­ent oral small mol­e­cules in Phase 1 test­ing, eyes about $88.4 mil­lion …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

FDA ap­proves Lil­ly's Zep­bound for sleep ap­nea, like­ly crack­ing open Medicare mar­ket

Three drug­mak­ers sue US over 340B dis­counts to STD clin­ics they al­lege don’t qual­i­fy

A service from the Financial Times